Receptor News and Research

RSS

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States.

3 Sep 2015

Regulatory T cells may reduce susceptibility to allergies

Susceptibility to allergies reduced by increased production of regulatory T cells. This is the main finding of a current study being conducted at the Institute of Immunology at MedUni Vienna, headed up by Winfried F. Pickl. The initial results of this study by Alina Neunkirchner, which looks at the root cause of the development of allergies, are being presented at the European Congress of Immunology, which starts in Vienna this Sunday (6 - 9 September 2015, Austria Center Vienna).

3 Sep 2015

Scientists pinpoint neurons responsible for alcohol consumption

Scientists have pinpointed a population of neurons in the brain that influences whether one drink leads to two, which could ultimately lead to a cure for alcoholism and other addictions.

3 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

3 Sep 2015

Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal.

2 Sep 2015

Volatile anesthetics may combat viral and bacterial infections in the lung

In use for more than a century, inhaled anesthetics like nitrous oxide and halothane have made modern surgery possible. Now, in experiments in mice, researchers at Johns Hopkins and elsewhere have added to evidence that certain so-called "volatile" anesthetics -- commonly used during surgeries -- may also possess powerful effects on the immune system that can combat viral and bacterial infections in the lung, including influenza and pneumonia.

2 Sep 2015

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Among patients with diabetes and kidney disease, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of the medication finerenone compared with placebo resulted in improvement in albuminuria (the presence of excessive protein [chiefly albumin] in the urine), according to a study in the September 1 issue of JAMA.

2 Sep 2015

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist (MRA) called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide [NT-proBNP].

1 Sep 2015

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.

1 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

The combination drug valsartan/sacubitril known as LCZ696 significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker (ARB) olmesartan in patients with hypertension, according to results of the PARAMETER study.

31 Aug 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

ATTEMPT-CVD trial results show that ARBs may have better impact on CVD biomarkers

When it comes to treating high blood pressure, not all anti-hypertensive medications are equal, and results of the ATTEMPT-CVD trial suggest that telmisartan, an angiotensin II receptor blocker (ARB) might have benefits over non-ARB treatment.

31 Aug 2015

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia.

31 Aug 2015

MRA therapy does not improve outcome in heart attack patients without heart failure

Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.

31 Aug 2015

Genetic test that predicts recurrence of breast cancer may impact use of chemotherapy

A genetic test that helps predict whether some women's breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine.

28 Aug 2015

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell.

28 Aug 2015

Researchers uncover important cellular functions that help regulate inflammation

Researchers at the Virginia Bioinformatics Institute at Virginia Tech have uncovered key cellular functions that help regulate inflammation -- a discovery that could have important implications for the treatment of allergies, heart disease, and certain forms of cancer.

28 Aug 2015

Receptor News and Research

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

Regulatory T cells may reduce susceptibility to allergies

Scientists pinpoint neurons responsible for alcohol consumption

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Treatment with life-saving medications increases in IHD but levels still suboptimal

Volatile anesthetics may combat viral and bacterial infections in the lung

Finerenone drug improves albuminuria among patients with diabetes and kidney disease

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

ATTEMPT-CVD trial results show that ARBs may have better impact on CVD biomarkers

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

MRA therapy does not improve outcome in heart attack patients without heart failure

Genetic test that predicts recurrence of breast cancer may impact use of chemotherapy

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers uncover important cellular functions that help regulate inflammation

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News